for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

タカラバイオ株式会社

4974.T

現在値

2,891.00JPY

変化

-24.00(-0.82%)

出来高

547,900

本日のレンジ

2,877.00

 - 

2,952.00

52週レンジ

1,481.00

 - 

3,535.00

∙ 約20分前の相場を表示しています。

適時開示

Takara Bio signs agreement for co-development and sales rights in Japan to NY-ESO-1 siTCRTM and CD19 CAR gene therapies

April 9(Reuters) - Takara Bio Inc <4974.T>:Says it has entered into an agreement with Otsuka Pharmaceutical Co., Ltd for co-development and exclusive sales rights in Japan for Takara's NY-ESO-1 siTCRTM (TBI-1301, TBI-1301-A) and CD19 CAR (TBI-1501) gene therapies.

Takara Bio say first patient enrolled into phase I clinical trial of Oncolytic Virus HF10 in Japan

Sept 27 (Reuters) - Takara Bio Inc <4974.T>:* Says the first patient with pancreatic cancer has been enrolled into Oncolytic Virus HF10(TBI-1401) phase I clinical trial in Japan on Sept. 26 .

Takara Holdings' subsidiary Takara Bio says merger between US-based units

Takara Bio Inc <4974.T> : Says the company's wholly owned US-based sub-subsidiary Takara Bio USA Inc plans to merge with co's other two wholly owned US-based sub-subsidiaries Rubicon Genomics Inc and WaferGen Bio-systems Inc, with effective date on March 31 (for Rubicon) and May 31 (for WaferGen)respectively . Says units Rubicon Genomics and WaferGen Bio-systems will be dissolved after transaction .Says the company, Takara Bio Inc, is a consolidated subsidiary of Takara Holdings Inc <2531.T>.

Wafergen Bio-Systems expects total revenue for Q4 2016 to be about $3.9 mln

Wafergen Bio-systems Inc <WGBS.O>: Wafergen Bio-systems reports revenue growth in fourth quarter of 2016 . Sees FY 2016 revenue about $10.7 million . Wafergen Bio-Systems Inc - company expects total revenue for Q4 of 2016 to be approximately $3.9 million or a 62% increase .Wafergen Bio-Systems Inc - ended Q4 with cash of approximately $4.5 million, which includes initial $2.5 million advanced by Takara Bio USA Holdings, Inc.

Takara Bio to start phase I/II clinical trials of gene therapy for sarcoma treatment

Takara Bio Inc <4974.T>:Says the co to start phase I/II clinical trials of gene therapy for treatment of sarcoma.

Takara Bio's unit completes acquisition of Rubicon Genomics

Takara Bio Inc <4974.T> : Says its wholly owned subsidiary Takara Bio USA Holdings Inc completes acquisition of Rubicon Genomics, Inc on Jan. 17 (US local time) .Previous plan was disclosed on Dec. 15, 2016.

Takara Bio unit to buy Rubicon Genomics

Takara Bio Inc <4974.T>: Says its unit Takara Bio USA Holdings Inc plans to acquire Rubicon Genomics, Inc in early Jan. 2017 .Says transaction price expected at $75 million.

Takara Bio signs exclusive license agreement of Oncolytic virus HF10 with Otsuka Pharmaceutical

Takara Bio <4974.T>: Says it signed an exclusive license agreement of Oncolytic virus HF10 with Otsuka Pharmaceutical .Says it gives development and sale right of HF10 to Otsuka Pharmaceutical.

WaferGen Bio-Systems announces stockholder approval of merger with Takara Bio

WaferGen Bio-systems Inc <WGBS.O>: Wafergen Bio-Systems announces stockholder approval of merger with Takara Bio .Wafergen Bio-Systems Inc - "look forward" to closing transaction in Q1 of 2017.

Takara Bio launches fully differentiated, Cellartis hiPS beta cells for research use

Takara Bio Inc <4974.T> :Launch of fully differentiated, Cellartis hiPS beta cells for research use.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up